Abstract: Provided herein are an ?2-3 disialylated PSA protein standard and an ?2-6 disialylated PSA protein standard, as well as various methods for measuring the relative (fractional) amount of the total N-acetylneuraminic acid (Neu5Ac) that is ?2-3-linked N-acetylneuraminic acid (?2-3-linked Neu5Ac) and is ?2-6-linked N-acetylneuraminic acid (?2-6-linked Neu5Ac) on PSA present in a blood serum or plasma sample, which is useful for determining whether a subject has a low risk (GG1), intermediate risk (GG2) or a high risk (GG3, 4 or 5) prostate cancer and/or determining and/or treating whether a human subject suspected of having prostate cancer should receive a needle biopsy. Also included are methods of monitoring and treating a prostate cancer patient post prostate cancer removal surgery for need of additional cancer treatment.

Abstract: The present application provides pharmaceutical compositions comprising polyanionic and polynon-ionic cyclodextrin-based dendrimers. The compositions can be used as excipients, or to bind to compounds such as in the use as a rescue medicine to remove undesired drugs and metabolites from a subject Methods of use in treating a subject are also provided.

Abstract: The present application provides a multifunctional cyclodextrin dendrimer of the formula comprising at least one anionic residue and at least one non-ionic residue bound to the cyclodextrin ring structure, and methods of their manufacture. The multifunctional cyclodextrin dendrimer as described herein can be used for drug delivery.